EGFR and non-small cell lung carcinoma: Based on the results of a multicenter, nonrandomized, open-label, multicohort clinical trial (CHRYSALIS, NCT 02609776), the FDA granted accelerated approval for amivantamab on May 21, 2021, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations, whose disease has progressed on or after platinum-based chemotherapy2.